Pharmacophore modeling of cytochromes P450

被引:99
作者
de Groot, MJ [1 ]
Ekins, S
机构
[1] Pfizer Global Res & Dev, Dept Mol Informat Struct & Des, Sandwich Labs, Sandwich CT13 9NJ, Kent, England
[2] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
cytochrome P450; drug-drug interactions; pharmacophore models; 3D-QSAR; catalyst;
D O I
10.1016/S0169-409X(02)00009-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Understanding the binding of ligands in the active site of a membrane-bound protein is difficult in the absence of a crystal structure. When these proteins are the enzymes involved in drug metabolism, it leaves little option but to use site-directed mutagenesis and in vitro studies to provide critical information relating to determinants of binding affinity. Pharmacophore models and three-dimensional quantitative structure-activity relationships have been used either alone or in combination with protein homology models to provide this information for cytochrome P450s. At present, their application has been directed to the major enzymes but this may escalate in future as more in vitro data are generated for other P450s. The following review outlines the methodologies and models as well as future prospects for applying these technologies to P450s in the hope that future drugs will be selected with increased metabolic stability and fewer incidences of undesirable drug-drug interactions. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:367 / 383
页数:17
相关论文
共 104 条
[1]   Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis [J].
Afzelius, L ;
Zamora, I ;
Ridderström, M ;
Andersson, TB ;
Karlén, A ;
Masimirembwa, CM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :909-919
[2]   THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION [J].
ARMSTRONG, M ;
FAIRBROTHER, K ;
IDLE, JR ;
DALY, AK .
PHARMACOGENETICS, 1994, 4 (02) :73-81
[3]  
Bargar TM, 1999, PESTIC SCI, V55, P1059, DOI 10.1002/(SICI)1096-9063(199911)55:11&lt
[4]  
1059::AID-PS57&gt
[5]  
3.0.CO
[6]  
2-J
[7]   MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids [J].
Bravi, G ;
Gancia, E ;
Mascagni, P ;
Pegna, M ;
Todeschini, R ;
Zaliani, A .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (01) :79-92
[8]  
Bravi G, 2000, QUANT STRUCT-ACT REL, V19, P29, DOI 10.1002/(SICI)1521-3838(200002)19:1<29::AID-QSAR29>3.3.CO
[9]  
2-G
[10]   FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].
BROSEN, K ;
SKJELBO, E ;
RASMUSSEN, BB ;
POULSEN, HE ;
LOFT, S .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214